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In 2017, an estimated 222,500 new cases of lung can-cer were diagnosed and more than 155,800 people died 
from lung cancer [1]. In 2011, the National Lung Screening 
Trial (NLST) found a 20% reduction in lung cancer mortal-
ity when high-risk patients, defined as those aged 55–74 
years who were current or former (quit within the past 15 
years) smokers with a 30 pack-year smoking history, were 
screened annually with low-dose computed tomography 
(LDCT) as compared to chest radiography [2]. This mor-
tality benefit led to a Grade B endorsement for lung cancer 
screening with LDCT by the US Preventive Services Task 
Force (USPSTF) in December of 2013 [3]. Recommendations 
for lung cancer screening vary among professional societies 
with respect to their criteria for identifying high-risk patients 
based on age and smoking status, but it is widely accepted 
to screen patients who meet the NLST criteria. The National 
Comprehensive Cancer Network (NCCN) [4], the American 
Lung Association (ALA) [5], the American Cancer Society 
(ACS) [6], the American Thoracic Society (ATS) [7], the 
American Society of Clinical Oncologists (ASCO) [8], and 
the American College of Chest Physicians (ACCP) [7] rec-
ommend that individuals at high risk for lung cancer con-
sider annual screening with LDCT. In contrast, the American 
Academy of Family Physicians (AAFP) states that there is 
insufficient evidence to recommend for or against screening 
for lung cancer with LDCT [9]. Since January 2015, private 
insurance payers have covered lung cancer screening and 
in February 2015, the Centers for Medicare and Medicaid 
Services (CMS) began providing reimbursement for lung 
cancer screening in high-risk individuals [6, 5, 10]. Under 
the USPSTF guidelines, an estimated 8.7 million US adults fit 
within the screening-eligible population [11].  
Prior research has found that physician attitudes, beliefs, 
and knowledge about lung cancer screening directly impact 
the number of reported screening exams ordered [12-14]. 
Barriers to screening commonly cited by physicians include 
uncertainty of patient benefits, patient financial burdens, 
and concern regarding potential harms [15-18]. Although 
lung cancer screening attitudes, beliefs, and knowledge 
have been examined among primary care providers (PCPs) 
and specialists, no studies to date have compared physician 
opinions and practices by specialty in the same medical cen-
ter. Evaluating differences by specialty will allow us to iden-
tify the extent to which our lung cancer screening program 
is being implemented equally across the health care system 
and points for further education and communication among 
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physicians. Therefore, we sought to understand the prac-
tices and attitudes of pulmonologists and PCPs in a large 
academic medical center. 
Materials and Methods
Survey Development
Using the Tailored Design Method, we conducted a 
web-based survey (using Qualtrics survey software) of 
physicians in Family Medicine, Internal Medicine, and 
Pulmonology in 2015 [19]. The Tailored Design Method is an 
approach to designing surveys that emphasizes all aspects 
of questionnaire and survey implementation procedures 
and focuses on reducing 4 dominant sources of survey 
error: sampling, coverage, measurement, and nonresponse. 
Survey questions were developed through collaboration with 
a multidisciplinary Advisory Group, which included 7 mem-
bers from the following fields of study: Internal Medicine, 
Family Medicine, Thoracic Radiology, Pulmonary Medicine, 
Pathology, Survey Methodology, and Epidemiology. Over the 
course of 6 conference calls and follow-up correspondence, 
we discussed survey themes, developed specific questions, 
and revised our survey instrument. We included 23 survey 
items focused on opinions about lung cancer screening, lung 
cancer screening practices, perceived barriers to lung can-
cer screening, and physician demographics. Survey ques-
tions were comprised of Likert scale items, clinical vignettes, 
and multiple choice. The survey was pre-tested with 5 North 
Carolina physicians in primary care or pulmonology who 
practice outside of the participating academic center. These 
physicians provided feedback with regard to survey flow, 
length, design, and ease of understanding and responding 
to the survey questions. Responses from the pre-testing led 
to modifications to clarify the intent of several questions. 
The survey was conducted after the USPSTF guideline was 
issued. During the time of this survey, lung cancer screening 
had been adopted at our institution by some providers and 
clinics. Preliminary data indicated that lung cancer screen-
ing was fragmented, and few patients were being screened. 
The survey was designed to help further understand physi-
cians’ behaviors and screening patterns.
Physician lung cancer screening opinions were evaluated 
via a 5-point Likert scale that ranged from strongly agree to 
strongly disagree. The survey asked physicians to rank their 
opinion on 6 statements: 1) I am convinced that screening 
for lung cancer is beneficial for patients; 2) inconsistent rec-
ommendations about lung cancer screening make it difficult 
to decide whether or not to screen; 3) screening for lung 
cancer is cost-effective; 4) I rely on the recommendations 
of local specialists regarding lung cancer screening in my 
practice; 5) I have enough knowledge to explain the pros and 
cons of lung cancer screening to my patients; and 6) time 
restrictions during a patient’s clinic visit mean other condi-
tions have higher priority over screening for lung cancer.  
Physician lung cancer screening practices were assessed 
through 5 clinical vignettes of hypothetical patient sce-
narios to assess knowledge of screening guidelines and to 
show the complexities involved in making screening deci-
sions. Vignette 1 consisted of a healthy 60-year-old for-
mer smoker with a 30 pack-year history who quit smoking 
1 year ago. Vignette 2 included a healthy 55-year-old for-
mer smoker with a 15 pack-year history who quit smoking 
20 years ago. Vignette 3 consisted of a healthy 62-year-old 
former smoker with a 40 pack-year history who quit smok-
ing 16 years ago and was exposed to asbestos in the work-
place. For each vignette, physicians were asked if they would 
or would not recommend lung cancer screening with LDCT, 
or if they would request additional information. Since differ-
ing organizations have varying recommendations for lung 
cancer screening (in terms of age at which to screen, smok-
ing history, and other factors), there is no one correct answer 
for each vignette. For vignette 1, all organizations except the 
AAFP recommend screening. In vignette 2, the fact that the 
patient quit smoking 20 years ago indicates that they do not 
meet USPSTF, ALA, ACS, ATS, ASCO, or ACCP guidelines 
for screening, although they do meet the NCCN criteria. 
For vignette 3, the patient is outside the 15 year-since-quit 
window so does not meet most organizations’ criteria for 
screening, but the patient has exposure to asbestos so may 
be suitable for screening if it were risk-based.  
Additional survey questions included whether the physi-
cian had ordered a LDCT for lung cancer screening in the 
past 12 months, if they had initiated discussion regarding 
the risks and benefits of screening, if they had discussed 
the results of an LDCT screening exam with a patient, or if 
they had referred a patient for lung cancer screening. These 
questions were based on those from the 2006 National 
Cancer Institute Colorectal and Lung Cancer Screening 
Questionnaire [20]. Questions also included whether or 
not a physician had received requests from patients for lung 
cancer screening in the past 12 months, and if so, how many 
requested screening. Lastly, the survey included a question 
regarding patient referrals for a smoking cessation program. 
In order to determine awareness of guidelines concern-
ing lung cancer screening, physicians were given a list 
of professional organizations that have published state-
ments concerning lung cancer screening and were asked if 
these organizations recommend for or against lung cancer 
screening. 
To ascertain physician-perceived barriers to lung cancer 
screening, we provided a list related to test performance 
issues, patient-related issues, health care access issues, and 
medical complications. Physicians were asked to select all 
perceived barriers. Lastly, physician demographics included 
age, race, ethnicity, gender, medical division, the number of 
years in clinical practice, the percent of effort dedicated to 
patient care, and the number of patients typically seen in 
their clinic.  
Survey Deployment 
We identified physicians in Family Medicine, Internal 
Medicine, and Pulmonary Medicine groups through our aca-
demic online directories. We mailed each participant a pre-
notification postcard to introduce the study and survey. One 
week later, a survey link was emailed to each participant. At 
1, 4, 8, and 9 weeks post-survey delivery, reminder emails 
were sent to those who had not yet responded. A reminder 
postcard was mailed 2 weeks after survey deployment. 
The survey was conducted online with responses recorded 
directly in Qualtrics at the time of survey completion, then 
exported for analysis in SAS v9.4 (SAS Institute, Inc., Cary, 
NC). Consent for the study was determined by return of the 
survey. As an incentive, those who participated were given 
the opportunity to enter into a random drawing for an iPad. 
We limited our survey to 23 items and included an incentive, 
as prior work has shown this to increase physician response 
rates [21-23]. This study was reviewed and approved by 
the University of North Carolina at Chapel Hill Institutional 
Review Board. 
Statistical Analysis
We combined Family Medicine and Internal Medicine 
physicians into a PCP group, as the majority of patients eli-
gible for screening will be identified from these 2 groups 
and both groups provide primary care. We compared PCP 
responses with physicians in Pulmonary Medicine using 
t-tests for continuous outcomes and χ2 tests for categorical
outcomes.
Results 
The overall survey response rate was 40% and by phy-
sician group was 50% for pulmonologists (17 of 34) and 
38.7% for PCPs (72 of 186). Within the PCP group, 37 were 
from Family Medicine and 35 were from Internal Medicine. 
Approximately 58.3% of PCPs were attending physicians 
and 41.7% were resident physicians, whereas 64.7% of 
pulmonologists were attending physicians and 35.3% were 
resident physicians. The mean age of pulmonologists and 
PCPs was similar (see Table 1). Compared with PCPs, pul-
monologists spent less time in outpatient care (mean time 
45% versus 29%, respectively) and saw fewer patients per 
week. Physicians in Family Medicine and Internal Medicine 
were similar with respect to age, sex, race, years in clinical 
practice, percent of time spent in outpatient care, and the 
average number of patients seen per week. 
The majority of respondents agreed that they had 
enough knowledge to explain the pros and cons of lung 
cancer screening to their patients. Most pulmonologists 
agreed that lung cancer screening is beneficial for patients, 
while most PCPs disagreed or were undecided (P < .001) 
(see Table 2). Pulmonologists were more likely to report 
screening as cost-effective (P = .02) and that they rely on 
recommendations of local specialists when making lung 
cancer screening decisions compared with PCPs (P < .001). 
It is important to note that within pulmonology there are 
screening specialists. PCPs were significantly more likely 
than pulmonologists to report that time restrictions dur-
ing a patient’s visit led to other presenting problems having 
higher priority than lung cancer screening (P = .012). Within 
the PCP group, Family Medicine and Internal Medicine phy-
sicians had similar answers except for the question “I have 
enough knowledge to explain the pros and cons of lung 
cancer screening to my patient,” for which Family Medicine 
physicians were more likely to report being undecided than 
Internal Medicine (31% versus 3%).
The majority of pulmonologists and PCPs correctly 
identified that the USPSTF and the ACS recommend lung 
table 1.
Characteristics of Survey Respondents by Provider Specialty
Pulmonologists Primary care providers 
N = 17 N = 72
N or % N or % 
Mean (Range) Mean (Range)
Age, mean 40.8 (29–67) 39.7 (28–64)
# Missing 2 9 
Sex
 Female 5 31.3 34 53.1
 Male 11 68.8 30 46.9
 Missing 1 - 8 -
Race
 White 12 75.0 57 89.1
 Non-white 4 25.0 7 10.9
 Missing 1 - 8 -
Years in clinical practice, mean 13.4 (2–35) 11.0 (1–35)
# Missing 1 8 
% Time in outpatient care, mean 29.4 (10–70) 44.5 (5–100)
# Missing 1 7 
Average # patients seen in outpatient/week 16.7 (6–50) 28.0 (3–100)
# Missing 1 7 
cancer screening (see Table 3). However, a higher propor-
tion of pulmonologists knew that the ACCP recommends 
screening compared with PCPs (76.5% versus 38.5%, 
respectively). Very few pulmonologists or PCPs knew that 
the AAFP does not endorse lung cancer screening. Among 
PCPs, Family Medicine and Internal Medicine physicians 
had similar responses except for the AAFP organization, for 
which Family Medicine physicians were more likely to report 
yes than Internal Medicine (34% versus 9%), more likely to 
report no (25% versus 6%), and less likely to report not sure 
(41% versus 84%).
In the clinical vignettes (see Table 4), pulmonologists and 
PCPs reported similar responses. Both recommended LDCT 
most often for vignette 1 (81% of PCPs and 100% of pulmo-
nologists), the scenario that met recommended screening 
guideline criteria for all organizations except the AAFP. For 
table 2.
Lung Cancer Screening Opinions by Provider Specialty
Pulmonologists Primary care providers 
N = 17 N = 72 P value
Statement N % N %
I am convinced that screening for lung cancer is beneficial for patients
Strongly agree 6 35.3 4 5.8 < 0.001
 Agree 9 52.9 22 31.9
 Undecided 2 11.8 33 47.8
 Disagree 0 0 10 14.5
Strongly disagree 0 0 0 0
 Missing 0 – 3 –
Inconsistent recommendations about lung cancer screening make it difficult to  
decide whether or not to screen
Strongly agree 2 11.8 8 11.4 0.667
 Agree 5 29.4 34 48.6
 Undecided 2 11.8 7 10.0
 Disagree 7 41.2 18 25.7
Strongly disagree 1 5.9 3 4.3
 Missing 0 – 2 –
Screening for lung cancer is cost-effective 
Strongly agree 0 0 1 1.4 0.020
 Agree 8 47.1 9 12.9
 Undecided 8 47.1 41 58.6
 Disagree 1 5.9 11 15.7
Strongly disagree 0 0 8 11.4
 Missing 0 – 2 – 
I rely on the recommendations of local specialists regarding lung cancer screening  
in my practice 
Strongly agree 3 19.7 0 0 < 0.001
 Agree 9 52.9 16 23.2
 Undecided 0 0 12 17.4
 Disagree 5 29.4 35 50.7
Strongly disagree 0 0 6 8.7
 Missing 0 – 3 –
I have enough knowledge to explain the pros and cons of lung cancer screening  
to my patients 
Strongly agree 4 25.0 9 13.0 0.299
 Agree 9 56.3 33 47.8
 Undecided 3 18.8 12 17.4
 Disagree 0 0 14 20.3
Strongly disagree 0 0 1 1.5
 Missing 1 – 3 –
Time restrictions during a patient’s clinic visit mean other presenting problems have  
higher priority than screening for lung cancer 
Strongly agree 2 11.8 10 14.7 0.012
 Agree 5 29.4 36 52.9
 Undecided 7 41.2 8 11.8
 Disagree 2 11.8 14 20.6
Strongly disagree 1 5.9 0 0
 Missing 0 – 4 –
vignette 2, the majority of both groups recommended no 
screening in accordance with the USPSTF, ACS, ALA, ATS, 
ASCO, and ACCP guidelines. In vignette 3, providers were 
split, with 47.1% of pulmonologists and 51.5% of PCPs rec-
ommending LDCT. In this vignette, a similar proportion said 
they would not screen and slightly more pulmonologists said 
they needed more information than PCPs (35% versus 25% 
respectively). The responses for vignette 3 indicate the com-
plexities involved in making decisions around lung cancer 
screening. Family Medicine and Internal Medicine reported 
similar responses for all clinical vignettes.
During the 12 months preceding the survey, 76.5% of 
pulmonologists reported ordering a LDCT for lung cancer 
screening, compared to 41.2% of PCPs (P = .002) (see Table 
5). A similar proportion of both pulmonologists (70.6%) 
and PCPs (41.8%) who ordered a LDCT reported discuss-
ing results of the scan with their patient. Less than 15% of 
physicians reported referring a patient to another provider 
for evaluation of lung cancer screening. Over 90% of pul-
monologists and PCPs reported referring patients to various 
smoking cessation programs during the prior 12 months. 
Within PCPs, Internal Medicine physicians were more likely 
to report yes than Family Medicine (58% versus 42%) for 
the question “In last 12 months, did you discuss results of 
LDCT for lung cancer screening?”
Pulmonologists and PCPs reported similar barriers for 
recommending or referring patients for lung cancer screen-
ing. The most commonly cited barrier was cost to patients 
(82.4% of pulmonologists and 77.8% of PCPs). Other bar-
riers to screening included potential for emotional harm 
(58.8% pulmonologists and 58.3% PCPs), potential for 
complications (47.1% pulmonologists and 59.7% PCPs), 
too many false positives (47.1% pulmonologists and 69.4% 
PCPs), cost to the health care system (47.1% pulmonologists 
and 54.2% PCPs), and low patient acceptance (41.2% pul-
monologists and 37.5% PCPs). 
Discussion
Based on our survey, significant differences existed in 
opinions and practices of pulmonologists and PCPs regard-
ing lung cancer screening. Pulmonologists were more likely 
than PCPs to report positive aspects of lung cancer screen-
ing, such as the benefit to patients and cost-effectiveness. 
A higher proportion of pulmonologists reported ordering a 
LDCT for lung cancer screening for an asymptomatic patient 
during the 12 months before the survey compared to PCPs. 
This may be due to the higher prevalence of chronic heavy 
smokers in pulmonology clinics than in PCP practices. It is 
also possible that PCPs may be referring patients to special-
ists for further evaluation and the specialists may be order-
ing the LDCT exam. In our study, factors likely to contribute 
to LDCT ordering rates were similar between groups, such 
as having sufficient knowledge to initiate conversation and 
explain the risks and benefits of screening. One important 
difference that may explain some of the variation in ordering 
lung cancer screening is that PCPs more often reported time 
limitations during the patient’s visit compared with pulmo-
nologists. In addition, patient visits with pulmonologists are 
focused on lung- and breathing-related health, allowing for 
more time to consider lung screening as part of overall lung 
health.
Several prior studies surveyed family physicians and 
other PCPs regarding their attitudes and knowledge of lung 
cancer screening. A 2015 survey of family physicians in 
South Carolina identified similar barriers and perceived risks 
of screening as in our study [16]. Specifically, concern about 
patient stress or anxiety was a perceived risk among 52% 
of family physicians, compared to the 58% of PCPs in our 
survey who reported emotional harm to patients as a barrier. 
In 2 studies conducted among family physicians and PCPs, 
83%–88% expressed concern over the potential for unnec-
essary diagnostic procedures and false positive findings 
[12, 16], which is similar to PCPs in our study indicating con-
cern over false positives (69%) and potential for complica-
tions (60%) [16]. 
We found that pulmonologists and PCPs identified simi-
lar barriers to screening. Cost to the patient was the most 
often-cited concern, which is similar to the 2013 data from 
the Lewis study (87%) [12]. Although CMS began covering 
the cost of lung cancer screening in 2015, it is possible that at 
the time of our survey, physicians may not have been aware 
of this coverage or they may have been concerned that addi-
tional follow-up would increase out-of-pocket expenses. 
While insurance may cover the cost of the initial LDCT 
table 3.
Professional Organization Lung Cancer Screening Guideline Knowledge by Provider Specialty
Pulmonologists’ Primary care providers’ 
response response 
Recommend screening? Recommend screening? P value
Yes No Not sure Yes No Not sure 
Professional organization N (%) N (%) N (%) N (%) N (%) N (%)
US Preventive Services Task Force 13 (76.5)* 0 (0) 4 (23.5) 57 (87.7)* 4 (6.2) 4 (6.2) 0.067
American Cancer Society 10 (58.8)* 0 (0) 7 (41.2) 35 (53.9)* 2 (3.1) 28 (43.1) 0.743
American College of Chest Physicians 13 (76.5)* 0 (0) 4 (23.5) 25 (38.5)* 1 (1.5) 39 (60.0) 0.019
American Academy of Family Physicians 2 (11.8) 1 (5.9)* 14 (82.4) 14 (21.9) 10 (15.65)* 40 (62.5) 0.297
*Indicates correct choice.
screening test, follow-up diagnostic testing is likely subject 
to deductibles and further out-of-pocket expenses. Providers 
and patients are both increasingly aware of these expenses 
and some clinicians may be concerned about the financial 
strain of diagnostic tests [24]. Policy interventions aimed at 
reducing uncertainty regarding out-of-pocket expenses may 
help patients and providers make more informed decisions 
about screening.
In our study, 38% of PCPs agreed or strongly agreed 
that screening for lung cancer is beneficial for patients, 
which was similar to findings of prior studies examining 
the proportion of physicians who believe that screening 
reduces lung cancer mortality (41% and 42%, respectively) 
[12, 16]. Approximately 62% of PCPs in our study had ini-
tiated a discussion regarding the benefits and harms of 
screening, which is similar to the 72% of PCPs in the Los 
Angeles County study by Raz and colleagues [16]. In our 
study, 41% of PCPs reported ordering a LDCT for lung can-
cer screening in the prior 12 months, which is similar to other 
studies that reported 52%–53% [15, 16].
Prior work examining pulmonologists’ attitudes toward 
lung cancer screening includes a national survey to pulmon-
ologists in Veterans Health Administration clinics from July 
2013 to February 2014 and an international sample of ATS 
clinicians from March to April of 2014 [13, 18]. Among pul-
monologists in Veterans clinics, the most commonly cited 
barriers to screening were poor infrastructure and lack of 
clinical personnel. Respondents of the ATS survey who said 
they would screen an NLST-eligible patient reported the 
following barriers to screening: false positives (52%), over-
diagnosis (44%), and high cost to the health care system 
(33%) [13]. 
The AAFP does not currently recommend lung cancer 
screening, stating that the evidence is insufficient to recom-
mend for or against screening [9]. The AAFP has expressed 
concerns that lung cancer screening recommendations are 
based on a single study and that NLST results have not been 
replicated in community settings. While initial findings from 
the Lahey Hospital & Medical Center are similar to the can-
cer detection and incidental finding rates of the NLST [25], 
there remains a paucity of data on LDCT screening in real-
world settings. We found that most PCPs and pulmonolo-
gists were unsure of AAFP recommendations around lung 
cancer screening. While it is not surprising that pulmonolo-
gists lack this knowledge, less than 20% of PCPs knew the 
AAFP stance on lung cancer screening, which suggests that 
most PCPs are more aware of guidelines from the USPSTF. 
In our sample of providers, both pulmonologists and 
PCPs reported spending less than 50% of their time in out-
patient care (mean time 29% and 45%, respectively). The 
relatively low proportion of time spent in outpatient care 
is likely reflective of: 1) the inclusion of resident physicians 
who spend a significant amount of their time on inpatient 
work; 2) academic pulmonologists often spending more 
time in the inpatient setting, covering the intensive care unit 
and the pulmonary inpatient service; and 3) academic physi-
cians having teaching and research responsibilities that limit 
their practice time, as compared to community physicians. 
Limitations
Our study has several limitations. Surveyed physi-
cians were part of a large academic medical center, and 
our results may not be generalizable to other practice set-
tings. However, to our knowledge, our study is the first to 
survey both PCPs and pulmonologists in the same institu-
tion, allowing for a direct comparison. The responses are 
table 4.
Recommended Lung Cancer Screening Strategies for 3 Clinical Vignettes
Pulmonologists Primary care providers 
Recommend screening strategy Recommend screening strategy
Need Need P value 
No additional No additional 
screening LDCT information screening LDCT information 
Vignette Description N (%) N (%) N (%) N (%) N (%) N (%)
Healthy 60-year-old,  0 (0) 17 (100) 0 (0) 6 (8.8) 55 (80.9) 7 (10.3) 0.147 
former smoker that has  
1 a 30 pack-year history  
and quit smoking  
1 year ago
Healthy 55-year-old,  12 (70.6) 1 (5.9) 4 (23.5) 59 (86.8) 5 (7.4) 4 (5.9) 0.083 
former smoker that has  
 2 a 15 pack-year history  
and quit smoking  
20 years ago
Healthy 62-year-old,  3 (17.7) 8 (47.1) 6 (35.3) 16 (23.5) 35 (51.5) 17 (25.0) 0.672 
former smoker that has  
 3 a 40 pack-year history,  
quit smoking 16 years ago, 
and was exposed to  
asbestos in the workplace
Note. LDCT, low-dose computed tomography.
self-reported and some of the survey questions asked 
practitioners about events from the past 12 months, so it is 
possible that responses may be susceptible to recall bias. 
While our survey response rate of 40% was not ideal, it is 
in line with prior web-based surveys to physicians regard-
ing lung cancer screening, which ranged from 4.8% to 60% 
[12, 15, 16, 18]. In addition, there is the potential for non-
response bias given our overall response rate. Future studies 
should collect information on non-respondents or include 
auxiliary data on the sampling frame to address nonre-
sponse bias. It is also possible that survey responses could 
be subject to social desirability bias.
Conclusion
As lung cancer screening is now a covered preventive 
service in the United States, the role of the PCP will be criti-
cal for screening in the setting of patient care. Our survey 
showed that the majority of PCPs are uncertain about refer-
ring patients for lung cancer screening, citing concerns 
regarding potential harms and cost. Understanding the 
opinions, beliefs, knowledge, and practice patterns of PCPs 
and pulmonologists may result in improved educational pro-
grams and development of comprehensive infrastructures 
that strengthen support and collaboration among the vari-
ous physicians who are charged with providing this preven-
tive service.  
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table 5.
Lung Cancer Screening Practices by Pulmonologists versus Primary Care Providers
Pulmonologists Primary care providers 
N = 17 N = 72 P value
Statement N % N %
In last 12 months, did any of your patients ask if they should be screened for  
lung cancer with LDCT?
 Yes 8 50.0 18 27.3 0.203
 No 7 43.8 44 66.7
Don’t recall 1 6.3 4 6.1
 Missing 1 – 6 – 
In last 12 months, did you order LDCT for LCS?
 Yes 13 76.5 28 41.2 0.002
 No 3 17.6 40 58.8
Don’t recall 1 5.9 0 0
 Missing 0 – 4 – 
In last 12 months, did you initiate LCS discussion re benefits/harms?
 Yes 14 82.4 42 61.8 0.097
 No 2 11.8 25 36.8
Don’t recall 1 5.9 1 1.5 
 Missing 0 - 4 - 
In last 12 months, did you discuss results of LDCT for lung cancer screening?
 Yes 12 70.6 28 41.8 0.088
 No 5 29.4 35 52.2 
Don’t recall 0 0 4 6.0 
 Missing 0 – 5 – 
In last 12 months, did you refer patient to another provider for evaluation of  
lung cancer screening?
 Yes 1 5.9 10 14.7 0.539
 No 16 94.1 57 83.8
Don’t recall 0 0 1 1.5
 Missing 0 – 4 – 
Have you referred patients to any of the following smoking cessation programs?
 QuitlineNC 13 76.5 55 76.4 0.994
1-800-Quit NOW 13 76.5 52 72.2 0.723
Local Nicotine Dependence Program 13 76.5 45 62.5 0.277
ACS Freedom from Smoking 1 5.9 0 0 0.038
Alternative Provider 3 17.6 14 19.4 0.865
Any Program 16 94.1 66 91.7 0.736
Note. LCS, lung cancer screening; LDCT, low-dose computed tomography.
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